1567Simplification to elvitegravir/cobicistat/emtricitabine/tenofovir DF from ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir DF maintains HIV suppression and improves fasting triglycerides at week 48

© 2014 Gilead Sciences, Inc. All rights reserved. • STRATEGY-PI is an ongoing Phase 3b trial evaluating the safety and efficacy of a regimen simplification strategy: continuation of a multi-tablet ritonavir-boosted protease inhibitor (PI + RTV) with emtricitabine and tenofovir DF (FTC/TDF) versus simplification to the single-tablet regimen consisting of elvitegravir, cobicistat, emtricitabine, and tenofovir DF (EVG/COBI/FTC/TDF)1 • Antiretroviral therapy simplification to reduce pill burden and/ or dosing frequency may improve treatment adherence, virologic outcome, and health-related quality of life2-3 • Other benefits of ritonavir-boosted PI regimen simplification may include improvement in fasting lipid parameters including triglycerides4,5 • In the D:A:D Study, a higher triglyceride concentration was marginally independently associated with an increased risk of myocardial infarction6 • We examine absolute changes and associated categorical shifts in fasting lipids as defined by the National Cholesterol Education Program (NCEP) in the STRATEGY-PI Study7